# TERMS OF REFERENCE AND PROFILE FOR MEMBERS OF GROUPS OF EXPERTS AND WORKING PARTIES

2	
3	
4	

5

6 7

8

1

The terms of reference and profiles shown below have been drafted by the Presidium to aid national authorities when making proposals for appointment. In addition to the profile described, national authorities should also ensure that the experts proposed are available to attend meetings and are prepared to draft and/or verify monographs and general chapters and when required in the profile, have access to a laboratory for experimental verifications.

9 Each group of experts and working party will advise the Commission and other groups of experts and 10 working parties where relevant, according to their expertise and contribute to the maintenance of the 11 relevant technical guide where appropriate.

The chairs of the following groups are members of the PCM working party: Groups 6, 7, 9, 10A/B/C/D, 11, 13H, 14, 17, P4 and MG WP. The chairs of the other groups of experts and working parties may be invited on an ad hoc basis, depending on the agenda. The Chair of the Ph. Eur. Commission is chairing the PCM and ROP working parties.

In the context of this document, the term "regulatory authority" encompasses OMCLs, licensing authorities, NPAs and/or inspectorates.

1718

19	Group of Experts No. 1 (Microbiology)	3
20	Group of Experts No. 6 (Biological and Biotechnological products)	4
21	Group of Experts No. 6B (Human Plasma and Plasma Products)	5
22	Group of Experts No. 7 (Antibiotics)	5
23	Group of experts No. 9 (Inorganic Chemistry)	5
24	Group of Experts No. 9G (Medicinal Gases)	6
25	Group of Experts No. 10A/B/C/D (Organic chemistry – synthetic and semi-synthetic substances)	6
26	Group of Experts No. 11 (Organic chemistry – natural, semi-synthetic and synthetic substances)	7
27	Group of Experts No. 12 (Dosage forms and pharmaceutical technical procedures)	7
28	Group of Experts No. 13A/B (Herbal Drugs and Herbal Drug Preparations)	8
29	Group of Experts No. 13H (Fatty oils and derivatives, polymers)	8
30	Group of Experts No. 14 (Radiopharmaceutical Preparations)	9
31	Group of Experts No. 15 (Human Vaccines and Sera)	9
32	Group of Experts No. 15V (Veterinary Vaccines and Sera)	10
33	Group of Experts No. 16 (Plastic materials, plastic containers and closures)	10
34	Group of Experts 17 (Medicinal products containing chemically defined active substances)	11
35	Group of Experts P4	11
36	ALG Working Party (Allergens)	12
37	ALU Working Party (Aluminium in parenteral nutrition solutions)	12
38	AQbD Working Party (Analytical quality by design)	13
39	BACT Working Party (Bacteriophages)	13
40	BET Working Party (Bacterial Endotoxin Test)	13
41	BSR Working Party (Bovine serum)	14
42	CE Working Party (Capillary Electrophoresis)	14
43	CEL Working Party (Cellulose)	15
44	CRB Working Party (Carbohydrates)	15
45	CST Working Party (Chromatographic separation techniques)	16
46	CTP Working Party (Cell Therapy Products)	16
47	DIA Working party (Dialysis)	16

1	EDSForm Working Party (European drug shortages Formulary)	
2	EXP Working Party (Excipient performance)	. 18
3	EXS Working Party (Excipient Strategy)	. 18
4	GLS Working Party (Glass Containers)	. 19
5	GTP Working Party (Gene Therapy Products)	. 19
6	HMM Working Party (Homoeopathic Manufacturing Methods)	. 20
7	HOM Working Party (Homoeopathic Raw Materials and Stocks)	. 20
8	HTS Working Party (High Throughput Sequencing for the detection of extraneous agents)	. 21
9	INH Working Party (Inhalations)	. 21
10	MAB Working Party (Monoclonal Antibodies)	. 22
11	MG Working Party (General methods)	. 22
12	mRNAVAC Working Party (mRNA Vaccines for human use)	. 23
13	MYC Working Party (Mycoplasma)	. 23
14	NANO Working Party (Nanomedicines)	
15	P4BIO Working Party (P4 Bio)	. 24
16	PaedF Working Party (European Paediatric Formulary)	. 24
17	PAT Working Party (Process Analytical Technology)	
18	POW Working Party (Powder Characterisation)	. 25
19	PRP Working Party (Precursors for Radiopharmaceutical Preparations)	
20	PST Working Party (Pesticide Residues)	
21	ROP Working Party (Rules of Procedure)	. 26
22	SDA Working Party (Spectroscopy and Data Analysis)	. 27
23	SIT Working Party (Second identification test)	. 27
24	ST Working Party (Standard Terms)	
25	SUT Working Party (Sutures)	. 28
26	TCM Working Party (Traditional Chinese Medicines)	
27	VIT Working Party (Vitamins)	
28	WAT Working Party (Water)	. 29
29		
30	Group of Experts No. 1 (Microbiology)	
31	Terms of reference	
32	<ul> <li>Drafting and revision of general chapters in the field of microbiology</li> </ul>	
33	<ul> <li>Advising the Commission on questions related to microbiological quality, including qua</li> </ul>	ality
34	attributes in monographs drafted by other groups of experts and working parties	•
35	<ul> <li>International harmonisation of general chapters in the field of microbiology</li> </ul>	
36	<ul> <li>Drafting and revision of general chapters in the field of alternative microbiological meth</li> </ul>	ods
37	(the so called "rapid methods")	
38	Assessment of proposed examples in view of their inclusion in document: "Examples	s of
39	validation protocols for alternative microbiological methods according to chapter 5.1.6", to	be
40	published on the EDQM website.	
41	Profile for experts	

Current expertise in microbiological analytical methods, related to quality control of active

substances, excipients and medicinal products and in development of control methods

1	<ul> <li>Several years of experience in one or more of the following fields</li> </ul>
2 3	<ul> <li>Microbiological quality control in a pharmaceutical manufacturing setting, in a hospital environment or in an independent testing laboratory</li> </ul>
4	<ul> <li>Market surveillance of microbiological quality in a regulatory authority</li> </ul>
5	<ul> <li>Assessment of the relevant parts of applications for marketing authorisation</li> </ul>
6 7	<ul> <li>Development of microbiological control methods in a research and development environment</li> </ul>
8 9	Profile for ad-hoc specialists on alternative microbiological methods (please indicate this field of expertise on the nomination form, if applicable)
10 11	<ul> <li>Current expertise in microbiological analytical methods, related to quality control of active substances, excipients and medicinal products and in development of control methods</li> </ul>
12	<ul> <li>Several years of experience in one or more of the following fields:</li> </ul>
13 14	<ul> <li>Validation of alternative microbiological methods in a pharmaceutical manufacturing setting, in a hospital environment or in an independent testing laboratory</li> </ul>
15 16	<ul> <li>Market surveillance of microbiological quality in a regulatory authority using alternative microbiological methods</li> </ul>
17	<ul> <li>Assessment of the relevant parts of applications for marketing authorisation</li> </ul>
18 19	<ul> <li>Development of alternative microbiological control methods in a research and development environment</li> </ul>
1)	development environment
20	Group of Experts No. 6 (Biological and Biotechnological products)
21	Terms of reference
22 23	<ul> <li>Drafting and revision of texts in the field of biological products, biotechnological products, including glycoproteins, and synthetic peptides</li> </ul>
24	<ul> <li>International harmonisation of general chapters in the field of biological products</li> </ul>
25	Profile for experts
26 27	<ul> <li>Current expertise in quality control of biological products, biotechnological products (including glycoproteins), peptides</li> </ul>
28 29 30	<ul> <li>Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of analytical procedures and drafting of texts</li> </ul>
31	<ul> <li>Several years of experience in one or more of the following fields:</li> </ul>
32 33	<ul> <li>Quality control of biological products, biotechnological products, including glycoproteins or of peptides in a pharmaceutical manufacturing setting</li> </ul>
34	<ul> <li>Quality control in a regulatory authority</li> </ul>
35	<ul> <li>Quality control of biological or biotechnological products, including glycoproteins, or</li> </ul>
36	of peptides in an independent testing laboratory
37	o Development of analytical procedures for control of biological or biotechnological
38 39	products, including glycoproteins or of peptides in a research and development environment
40	<ul> <li>Analytical procedure development and verification in a regulatory authority</li> </ul>
41	<ul> <li>Assessment of the relevant parts of application for marketing authorisation of</li> </ul>
42	biological and biotechnological products within a medicines agency

## Group of Experts No. 6B (Human Plasma and Plasma Products)

2 Terms of reference

1

3

5

6 7

8

9

10

11

12 13

14

15

16

17

18

19

22

23

24

26

27

28 29

30

3132

33

34

35

36

37

3839

40

42

- Drafting and revision of texts in the field of blood products
- 4 Profile for experts
  - Current expertise in the field of blood products, notably related to their quality control and development of analytical procedures for control of these products
  - Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of analytical procedures and drafting of texts
  - Several years of experience in one or more of the following fields:
    - Quality control of blood products in a pharmaceutical or bulk manufacturing setting
    - Batch release or market surveillance of Human Blood, Plasma and Plasma Products in a regulatory authority
      - Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
      - Quality control of blood products in an independent testing laboratory
    - o Analytical procedure development and verification in a regulatory authority
    - Development of analytical procedures for control of Human Plasma and Plasma Products in a research and development environment

## 20 Group of Experts No. 7 (Antibiotics)

- 21 Terms of reference
  - Drafting and revision of texts in the field of antibiotic active substances and medicinal products containing such substances
  - Provision of expertise in the field of antibiotics to Group 17 where relevant
- 25 Profile for experts
  - Current expertise in the fields of antibiotics
  - Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of analytical procedures and drafting of texts
  - Several years of experience in one or more of the following fields:
    - o Quality control of antibiotics in a pharmaceutical manufacturing setting
    - Quality control of antibiotics in a bulk manufacturing setting
    - Quality control of antibiotics in a regulatory authority
    - Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
      - o Quality control of antibiotics in an independent testing laboratory
      - Development of analytical procedures for control of antibiotics in a research and development environment
    - Analytical procedure development and verification in a regulatory authority

#### Group of experts No. 9 (Inorganic Chemistry)

- 41 Terms of reference
  - Drafting and revision of monographs in the field of inorganic substances

International harmonisation of monographs

## 2 Profile for experts

1

3

4 5

6 7

8

9

10

11

12

13

14

15

17

18

20

21

22

2324

25

26

27

28

29

30

32

3334

35

36

3738

3940

41

- Current expertise in pharmaceutical analytical procedures, related to quality control of inorganic substances and in development of such analytical procedures
  - Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs, for example ICP and/or AAS. **Essential**: Active involvement in laboratory verification of analytical procedures and drafting of texts.
  - Several years of experience in one or more of the following fields:
    - Quality control of inorganic substances in a pharmaceutical or bulk manufacturing setting
    - Market surveillance of quality in a regulatory authority
    - Pharmaceutical quality control in an independent testing laboratory
    - Development of analytical procedures for control of inorganic substances in a research and development environment
    - Analytical procedure development and verification in a regulatory authority

## 16 Group of Experts No. 9G (Medicinal Gases)

## Terms of reference

Drafting and revision of texts in the field of medicinal gases

## 19 Profile for experts

- Current expertise in the field of medicinal gases
- Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of analytical procedures and drafting of texts
- Several years of experience in one or more of the following fields:
  - Quality control of medicinal gases in a pharmaceutical manufacturing, hospital or industrial setting
  - Quality control in a regulatory authority
  - Development of analytical procedures for control of medicinal gases in a research and development environment

#### Group of Experts No. 10A/B/C/D (Organic chemistry – synthetic and semi-synthetic substances)

#### 31 Terms of reference

- Drafting and revision of monographs in the field of synthetic and semi-synthetic organic substances and medicinal products containing such substances
- If needed, provide expertise in the field of organic chemistry to Group 17

#### Profile for experts

- Current expertise in pharmaceutical analytical procedures, related to quality control of synthetic and semi-synthetic organic substances and/or medicinal products containing such substances and in development of such analytical procedures
- Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of analytical procedures and drafting of texts.
- Several years of experience in one or more of the following fields:

1	0	Quality control in a pharmaceutical manufacturing setting
2 3	0	Quality control of synthetic and semi-synthetic organic products and/or medicinal products containing such substances in a bulk manufacturing setting
4	0	Market surveillance of quality in a regulatory authority
5 6 7	0	Pharmaceutical quality control of synthetic and semi-synthetic organic substances and/or medicinal products containing such substances, in an independent testing laboratory
8 9 10	0	Development of analytical procedures for control of synthetic and semi-synthetic organic substances and/or medicinal products containing such substances in a research and development environment
11	0	Group 10D: development of analytical procedures for amino-acids
12	0	Analytical procedure development and verification in a regulatory authority
13	Group of Expe	rts No. 11 (Organic chemistry – natural, semi-synthetic and synthetic substances)
14	Terms of refere	ence
15 16		ng and revision of monographs in the field of natural, semi-synthetic and synthetic c substances and medicinal products containing such substances
17	<ul> <li>Provision of expertise in the field of organic chemistry to the Group 17 where relevant</li> </ul>	
18	Profile for expe	erts
19 20 21	natura	nt expertise in pharmaceutical analytical procedures, related to quality control of II, semi-synthetic and synthetic organic substances and/or medicinal products ning such substances, and in development of such analytical procedures
22 23 24	for inc	to laboratory facilities for verification and validation of analytical procedures proposed clusion in monographs, <b>Essential</b> : Active involvement in laboratory verification of ical procedures and drafting of texts.
25	<ul> <li>Severa</li> </ul>	Il years of experience in one or more of the following fields:
26	0	Quality control in a pharmaceutical manufacturing setting
27 28	0	Quality control of natural, semi-synthetic and synthetic organic substances and/or medicinal products containing such substances in a bulk manufacturing setting
29	0	Market surveillance of quality in a regulatory authority
30	0	Pharmaceutical quality control in an independent testing laboratory
31 32 33	0	Development of analytical procedures for control of natural, semi-synthetic and synthetic organic substances and/or medicinal products containing such substances in a research and development environment
34	0	Analytical procedure development and verification in a regulatory authority
35	Group of Expe	rts No. 12 (Dosage forms and pharmaceutical technical procedures)
36	Terms of refere	ence
37	<ul> <li>Draftir</li> </ul>	ng and revision of dosage form monographs and pharmaceutical technical procedures
38	• Mainte	enance of dosage form related International Harmonisation topics such as:
39	0	uniformity of dosage units
40	0	dissolution
41	0	disintegration

Particulate contamination: visible and sub-visible particles

• Provision of expertise in the field of pharmaceutical technology to other groups where relevant

42

2

3

4 5

6 7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

35

36

37

38

- Current expertise in pharmaceutical development and analytical procedures used for inprocess control and end product testing of pharmaceutical preparations, in the relevant specialities defined in the terms of reference
- Several years of experience in one or more of the following fields:
  - Development and quality control of pharmaceutical preparations in an industrial setting
  - Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  - Development of analytical procedures for testing of pharmaceutical preparations in a research and development environment
  - o Analytical procedure development and verification in a regulatory authority

## Group of Experts No. 13A/B (Herbal Drugs and Herbal Drug Preparations)

- Terms of reference
  - Drafting and revision of texts in the field of herbal drugs and herbal drug preparations
- Profile for experts
  - Current expertise in pharmaceutical analytical procedures, related to quality control of herbal drugs and herbal drug preparations and in development of such analytical procedures
  - Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of analytical procedures and drafting of texts.
  - Several years of experience in one or more of the following fields:
    - Quality control of herbal drugs and herbal drug preparations in a pharmaceutical manufacturing or bulk manufacturing setting
    - Market surveillance of quality of herbals in a regulatory authority
    - Assessment of the relevant parts of applications for marketing authorisation of herbal medicinal products within a medicines agency
    - Pharmaceutical quality control of herbal drugs and herbal drug preparations in an independent testing laboratory
    - Development of analytical procedures for control of herbal drugs in a research and development environment
    - o Analytical procedure development and verification in a regulatory authority

## Group of Experts No. 13H (Fatty oils and derivatives, polymers)

- 34 Terms of reference
  - Drafting and revision of texts in the field of:
    - surfactants
    - fatty oils, fats and waxes
    - o fatty acids, fatty alcohols and their esters/ethers
- 39 o macrogols, macrogol derivatives and other polymers (e.g. carbomers)
- 40 o paraffins
- International Harmonisation of the relevant monographs

1

2

3

4

5

6

7 8

9

10

11

1213

14

15

16

18

20

21

22

23

2425

2627

28 29

30

31

32

33

34

35

3738

40

41

- Current expertise in pharmaceutical analytical procedures, related to quality control in the relevant specialities defined in the terms of reference
- Member of a regulatory authority, universities or the pharmaceutical/chemical industries
- Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of analytical procedures and drafting of texts
- Several years of experience in one or more of the following fields:
  - Quality control in a pharmaceutical manufacturing setting
  - O Quality control of fats etc. in a bulk manufacturing setting
  - Market surveillance of quality in a regulatory authority
  - o Pharmaceutical quality control of fats etc. in an independent testing laboratory
  - Development of analytical procedures for control of fats etc. in a research and development environment
  - o Analytical procedure development and verification in a regulatory authority

#### **Group of Experts No. 14 (Radiopharmaceutical Preparations)**

## 17 Terms of reference

• Drafting and revision of texts in the field of radiopharmaceutical preparations

## 19 Profile for experts

- Current expertise in pharmaceutical analytical procedures, related to quality control of radiopharmaceutical preparations and in development of such analytical procedures
- Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of analytical procedures and drafting of texts
- Several years of experience in one or more of the following fields:
  - Quality control of radiopharmaceutical preparations in a pharmaceutical manufacturing setting or in a hospital
  - Market surveillance of quality of radiopharmaceutical preparations in a regulatory authority
  - Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  - Pharmaceutical quality control of radiopharmaceutical preparations in an independent testing laboratory
  - o Analytical procedure development and verification in a regulatory authority

#### Group of Experts No. 15 (Human Vaccines and Sera)

- 36 Terms of reference
  - Drafting and revision of texts in the field of vaccines and sera for human use
  - Drafting and revision of monographs in the field of botulinum toxins
- 39 Profile for experts
  - Current expertise in analytical procedures, related to quality control of vaccines and sera for human use and in development of such analytical procedures
- Several years of experience in one or more of the following fields:

2	<ul> <li>Quality control of vaccines and sera for human use in a pharmaceutical manufacturing setting</li> </ul>		
3 4	<ul> <li>Batch release and market surveillance of quality of vaccines and sera for human use in a regulatory authority</li> </ul>		
5 6	<ul> <li>Assessment of the relevant parts of applications for marketing authorisation within a medicines agency</li> </ul>		
7 8	<ul> <li>Quality control of vaccines and sera for human use in an independent testing laboratory</li> </ul>		
9 10	Profile for botulinum toxins ad hoc specialists (please indicate this field of expertise on the nomination form, if applicable)		
11 12	<ul> <li>Current expertise in analytical procedures for the control of botulinum toxins and in development of such analytical procedures</li> </ul>		
13	<ul> <li>Several years of experience in one or more of the following fields:</li> </ul>		
14	<ul> <li>Quality control of botulinum toxins in a pharmaceutical manufacturing setting</li> </ul>		
15 16	<ul> <li>Batch release or market surveillance of quality of botulinum toxins in a regulatory authority</li> </ul>		
17 18	<ul> <li>Assessment of the relevant parts of applications for marketing authorisation within a medicines agency</li> </ul>		
19 20	<ul> <li>Pharmaceutical quality control of botulinum toxins in an independent testing laboratory</li> </ul>		
21 22	<ul> <li>Development of analytical procedures for control of botulinum toxins in a research and development environment</li> </ul>		
23	Group of Experts No. 15V (Veterinary Vaccines and Sera)		
24	Terms of reference		
25 26	<ul> <li>Drafting and revision of texts in the field of immunological veterinary medicinal products (IVMP)</li> </ul>		
27	Profile for experts		
28 29	<ul> <li>Current expertise in suitable standards for IVMP, in analytical procedures related to quality control of these products and in development of such analytical procedures</li> </ul>		
30	<ul> <li>Several years of experience in one or more of the following fields:</li> </ul>		
31	<ul> <li>Quality control of IVMP in a regulatory authority</li> </ul>		
32 33	<ul> <li>Assessment of the relevant parts of applications for marketing authorisation within a medicines agency</li> </ul>		
34	<ul> <li>Batch release and market surveillance of quality in a regulatory authority</li> </ul>		
35 36	<ul> <li>Development of analytical procedures for control of IVMP in a research and development environment</li> </ul>		
37 38 39	<ul> <li>Industry representatives are normally not appointed to Group of Experts No. 15V. They may be invited to contribute to elaboration of texts during hearings organised on a case-by-case basis by the Secretariat.</li> </ul>		
40 41	Group of Experts No. 16 (Plastic materials, plastic containers and closures)		
TI	Group or Experts itor to (riustic inuterius), plustic tolltallicis alla diosales)		

# Group of Experts No. 16 (Plastic materials, plastic containers and closures)

Terms of reference 42

43

• Drafting and revision of texts in the field of plastic materials, plastic containers and closures

1

2

3

4

5

6

7

8 9

10

11

12

13

14

16

17

18 19

20

21

22

23

24

25

2627

28

29

30

31

32

33

34

35

37

38

40

41

42

- Current expertise in the fields covered by the terms of reference
- Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in texts, Essential: Active involvement in laboratory verification of analytical procedures and drafting of texts
- Several years of experience in one or more of the following fields:
  - o Quality control of plastic materials, plastic containers and closures
    - in a pharmaceutical manufacturing setting,
    - in a regulatory authority or
    - in an independent testing laboratory
  - Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  - Analytical procedure development and verification in a regulatory authority

#### Group of Experts 17 (Medicinal products containing chemically defined active substances)

#### 15 Terms of reference

- Drafting and revision of monographs on medicinal products containing chemically defined active substances (especially in case of a dosage form not yet covered by the technical guide)
- Drafting of monographs on active substances contained in these medicinal products if the monographs are being elaborated in parallel and if deemed appropriate;
- Provision of expertise to other groups where relevant

## Profile for experts

- Current expertise in pharmaceutical analytical procedures, related to quality control of medicinal products containing chemically defined active substances and in development of such analytical procedures
- Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of analytical procedures and drafting of texts.
- Several years of experience in one or more of the following fields:
  - Development and verification of analytical procedures
  - Quality control or development of medicinal products containing chemically defined active substances
  - Market surveillance testing
  - Assessment of the relevant parts of applications for marketing authorisation within a medicines agency

#### Group of Experts P4

#### 36 Terms of reference

• Drafting and revision of monographs in the field of single-source active substances, excipients and medicinal products with chemically defined active substances

#### 39 Profile for experts

 Current expertise in pharmaceutical analytical procedures, related to quality control of active substances, excipients and medicinal products (with chemically defined active substances), and in development of such analytical procedures

39

40

1 Access to laboratory facilities for verification and validation of analytical procedures proposed 2 for inclusion in monographs or access to licensing files, Essential: Active involvement in 3 laboratory verification of analytical procedures and drafting of texts. 4 • Several years of experience in one or more of the following fields: 5 Assessment of the relevant parts of applications for marketing authorisation 6 Market surveillance studies in a regulatory authority 7 Analytical procedure development and verification in a regulatory authority 8 • Group P4 is restricted to regulators from Ph. Eur. Member states however industry 9 representatives may be invited to contribute by submission of data and interaction with the group via the Secretariat 10 11 ALG Working Party (Allergens) Terms of reference 12 13 • Drafting and revision of texts in the field of allergen products 14 Profile for experts 15 Current expertise in pharmaceutical analytical procedures, related to quality control of allergens and in development of such analytical procedures 16 17 Several years of experience in one or more of the following fields: 18 Quality control of allergen products in a pharmaceutical manufacturing setting 19 Market surveillance of quality of allergen products in a regulatory authority Assessment of the relevant parts of applications for marketing authorisation within a 20 21 medicines agency 22 Pharmaceutical quality control of allergen products in an independent testing 23 laboratory 24 Development of analytical procedures for control of allergens in a research and 25 development environment 26 **ALU Working Party (Aluminium in parenteral nutrition solutions)** 27 Terms of reference 28 Drafting of general chapter on aluminium in parenteral nutrition solutions 29 Profile for experts 30 Current expertise in parenteral nutrition solutions, notably related to quality and 31 toxicological assessment of aluminium content, or in aluminium in parenteral preparations, 32 Several years of experience in one or more of the following fields Quality control of parenteral nutrition solutions and/or parenteral preparations 33 Assessment of the relevant parts of applications for marketing authorisation 34 Development and verification of analytical procedures for control of aluminium in 35 parenteral preparations and/or parenteral nutrition solutions 36 37 Market surveillance of quality of parenteral preparations and/or parenteral nutrition solutions in a regulatory authority 38

Preparation and administration of parenteral nutrition solutions or of parenteral

preparations in a clinical setting

#### AQbD Working Party (Analytical quality by design)

#### 2 Terms of reference

1

3

4

5

6

7

8 9

11 12

13

14

15

16 17

18 19

20

21

23

24

2526

27

28

29

30

31

32

33

36

37

38

39

40 41

- Assess the feasibility and impact of incorporating analytical procedures developed using the concepts of analytical quality by design (aQbD) in Ph. Eur. monographs.
  - Advise the Commission and expert groups on appropriate elaboration/revision strategies for incorporating such analytical procedures in monographs.
  - Identify verification and revision approaches for analytical procedures developed using aQbD.
  - Co-operation and consultation with other groups of experts and working parties in charge of the elaboration and revision of monographs, where relevant.

#### 10 Profile for experts

- Current expertise in the development of analytical procedures for the assessment of the quality of active substances and medicinal products
- Knowledge of pharmacopoeial monograph development
- Several years of experience in one or more of the following fields:
  - Development, validation and verification of analytical procedures, if possible applying aQbD concepts
  - Market surveillance testing
  - Assessment of the relevant parts of applications for marketing authorisation within a medicines agency, if possible with experience of assessing applications that used aQbD concept.

#### **BACT Working Party (Bacteriophages)**

- 22 Terms of reference
  - To elaborate the general chapter 'Phage therapy active substances and medicinal products for human and veterinary use'.

# Profile for experts

- Current expertise in analytical procedures related to quality control of bacteriophages and in development of such analytical procedures
- Several years of experience in one or more of the following fields:
  - Quality control of bacteriophages in a manufacturing setting
  - Preparation and administration of bacteriophages manufactured in a non-industrial way but of a quality compatible with clinical use (compassionate access)
  - Development of bacteriophages for clinical use
  - Analytical procedure development and verification in a regulatory authority

## 34 BET Working Party (Bacterial Endotoxin Test)

- 35 Terms of reference
  - Drafting and revision of general chapters in the field of bacterial endotoxins
  - Advising the Commission and expert groups on appropriate analytical procedures for the detection of bacterial endotoxins or pyrogens in substances for pharmaceutical use or pharmaceutical preparations.
  - Drafting and revision of general chapters in the field of the monocyte activation tests (MAT)
  - International Harmonisation of the relevant texts

#### 1 Profile for experts 2 Current expertise in practical application of the bacterial endotoxin test and/or MAT 3 Several years of experience in one or more of the following fields: 4 Quality control of parenteral preparations, active substances and/or excipients in a 5 pharmaceutical manufacturing setting Market surveillance of quality in a regulatory authority 6 Pharmaceutical quality control in an independent testing laboratory 7 8 Development of analytical procedures for bacterial endotoxin testing and/or MAT in a 9 research and development environment Analytical procedure development and verification in a regulatory authority 10 Access to laboratory facilities for verification and validation of analytical procedures proposed 11 for inclusion in monographs 12 13 14 **BSR Working Party (Bovine serum)** Terms of reference 15 • Maintenance of the monograph Bovine serum (2262) 16 17 Drafting and revision of other texts pertaining to bovine sera as appropriate 18 Profile for experts 19 Current expertise in analytical procedures related to quality control of bovine sera and in 20 development of such analytical procedures 21 Several years of experience in one or more of the following fields: 22 Quality control of bovine serum in a pharmaceutical manufacturing setting 23 Market surveillance of quality in a regulatory authority Assessment of the relevant parts of applications for marketing authorisation within a 24 25 medicines agency Pharmaceutical quality control in an independent testing laboratory 26 27 Development of analytical procedures for control of bovine serum in a research and development environment 28 **CE Working Party (Capillary Electrophoresis)** 29 30 Terms of reference 31 Revision of the chapter 2.2.47 Capillary electrophoresis 32 Advising the Commission on questions related to capillary electrophoresis in monographs 33 drafted by other groups of experts and working parties 34 International Harmonisation of the relevant texts Profile for experts 35

• Current expertise in Capillary electrophoresis techniques

authority or in any other testing laboratory

Quality control of active substances, excipients and medicinal products, using capillary

electrophoresis techniques, in a pharmaceutical manufacturing setting, in a regulatory

Several years of experience in the following fields:

3637

38

- Development of analytical procedures using capillary electrophoresis for control of active substances, excipients and medicinal products in a research and development environment or at university
  - Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs **Essential**: Active involvement in laboratory verification of analytical procedures and drafting of texts

#### **CEL Working Party (Cellulose)**

8 Terms of reference

4

5

6

7

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

2425

26

28

29

31

3233

34

35

3637

38

39

40 41

42

- Drafting and revision of monographs on cellulose and cellulose derivatives
- International harmonisation of monographs on cellulose and cellulose derivatives

#### Profile for experts

- Current expertise in analytical procedures for cellulose and cellulose derivatives and in development of such analytical procedures
- Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of analytical procedures and drafting of texts.
- Several years of experience in one or more of the following fields:
  - Quality control of cellulose and cellulose derivatives in a pharmaceutical or other industrial manufacturing setting
  - Market surveillance of quality of cellulose and cellulose derivatives in a regulatory authority
  - Quality control of cellulose and cellulose derivatives in a regulatory authority
  - Development of analytical procedures for control of cellulose and cellulose derivatives in a research and development environment
  - Analytical procedure development and verification in a regulatory authority

# CRB Working Party (Carbohydrates)

- 27 Terms of reference
  - Drafting and revision of monographs in the field of carbohydrates
  - International harmonisation of monographs
- 30 Profile for experts
  - Current expertise in pharmaceutical analytical procedures, related to quality control of carbohydrates and in development of such analytical procedures
  - Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of analytical procedures and drafting of texts.
  - Several years of experience in one or more of the following fields:
    - o Quality control in a pharmaceutical or bulk manufacturing setting
    - o Market surveillance of quality in a regulatory authority
  - Pharmaceutical quality control in an independent testing laboratory
    - Development of analytical procedures for control of carbohydrates in a research and development environment
    - Analytical procedure development and verification in a regulatory authority

#### CST Working Party (Chromatographic separation techniques)

2 Terms of reference

1

3

4

5

6 7

9

10

11

12

13

14

1516

17

18

20

21

22

24

25

26

27

28 29

30

3132

33

34

3536

37

38

39

40

42

- Revision of chapters on chromatographic separation (e.g. 2.2.28, 2.2.29, 2.2.30, 2.2.46)
  - Advising the Commission on questions related to chromatographic separation techniques in monographs drafted by other groups of experts and working parties
  - Co-operation with other groups of experts and working parties which use chromatographic separation techniques where relevant

#### 8 Profile for experts

- Current expertise in chromatographic separation techniques
- Several years of experience in one or more of the following fields:
  - Chromatographic quality control of active substances and/or excipients in a pharmaceutical manufacturing setting
  - Development of chromatographic analytical procedures for control of active substances, excipients and medicinal products in a research and development environment
  - Market surveillance of quality in a regulatory authority
  - o Pharmaceutical quality control in an independent testing laboratory

## CTP Working Party (Cell Therapy Products)

- 19 Terms of reference
  - Drafting and revision of texts in the field of cell-based preparations
  - Maintaining regular exchanges to ensure coordination of approaches with the GTP Working Party in relevant areas
- 23 Profile for experts
  - Current expertise in analytical procedures related to the development and quality control of cell therapy products and/or tissue-engineered products and/or to the quality control of tissues for human use
  - Several years of experience in one or more of the following fields:
    - o Development of cell therapy products and/or tissue-engineered products
    - Quality control of cell therapy products and/or tissue-engineered products in a pharmaceutical manufacturing setting or in a hospital environment and/or microbiological control of tissues and organs used for human transplantation
    - Assessment of applications for marketing authorisation of cell therapy and/or tissueengineered products
    - Market surveillance of the quality of cell therapy products, tissue-engineered products and/or tissues and organs used for human transplantation in a regulatory authority
    - o Pharmaceutical quality control in an independent testing laboratory
    - Development of analytical procedures (e.g. microbiological procedures) to control cell therapy products and/or tissue-engineered products and/or tissues and organs used for human transplantation in a research and development environment

# DIA Working party (Dialysis)

- 41 Terms of reference
  - Drafting and revision of texts in the field of preparations for dialysis

1

2

3

4

5

6 7

8

9

10

11

12

13

14

15

16

17

18

19

2021

2223

24

25

2627

28

29

30

31

32

33

34

36

37

38

39

40

41

42

43

44

45

- Current expertise in the field of preparations for dialysis
- Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs
- Several years of experience in one or more of the following fields:
  - Manufacture and/or quality control of preparations for dialysis in a pharmaceutical manufacturing setting or in a hospital
  - Quality control of preparations for dialysis in a regulatory authority
  - Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  - Quality control of preparations for dialysis in an independent testing laboratory
  - o Analytical procedure development and verification in a regulatory authority

## **EDSForm Working Party (European drug shortages Formulary)**

## Terms of reference

- Establishment and maintenance of the CD-P-PH & EPC approved framework for the European Drug Shortages Formulary describing the following items:
  - Criteria and guidelines for the selection, prioritisation and evaluation of appropriate pharmaceutical preparations from national formularies and other appropriate sources, taking into account relevant lists of essential medicines established by European competent authorities, that could be used to mitigate the negative impacts of potential drug shortages
  - o Criteria for evaluation of the suitability of production and quality control methods
  - Guidelines for the elaboration of monographs covering working methods, content and template
  - Guidelines for maintenance and vigilance of published monographs including criteria for revision/deletion and procedure for users/stakeholders/interested parties to raise potential issues.
- Selection, prioritisation, elaboration and revision of monographs describing standardised stock
  preparations of human medicines at risk of shortages according to the criteria and guidelines
  of the above-mentioned framework.
- In the event of active drug shortage, provide, if and when relevant, recommendations and guidance concerning pharmaceutical preparations that could be used to mitigate the negative impacts of the drug shortage.
- Establishment and maintenance of a respective Technical Guide and General Notices.

## 35 Profile for experts\*

- Current expertise in development and production of pharmaceutical extemporaneous and stock preparations
- Current expertise in analytical procedures related to quality control of ingredients (APIs and excipients) and pharmaceutical preparations and in their development
- Access to preparation or laboratory facilities for verification of production methods and analytical procedures proposed for inclusion in monographs
- Several years of experience in one or more of the following fields:
  - Pharmaceutical development and/or manufacturing of extemporaneous and stock pharmaceutical preparations (in a community or hospital pharmacy, research unit, or in pharmaceutical industry)

40 41

42

1 Analytical procedure development and verification of medicinal preparations in a 2 pharmaceutical manufacturing setting (including research and development), in a 3 regulatory authority, in a community or hospital pharmacy or in an independent 4 testing laboratory 5 Market surveillance of quality in a regulatory authority Assessment of the relevant parts of applications for marketing authorisation of 6 7 medicinal products (including safety assessment) 8 Elaboration/assessment of monographs for national or regional formularies 9 \*Observer(s) from the CD-P-PH are welcome to participate, especially during the establishment of the 10 framework 11 **EXP Working Party (Excipient performance)** 12 Terms of reference 13 Drafting and maintaining the FRC (Functionality Related Characteristics) sections of 14 monographs on excipients to reflect current best practices, in consultation with the 15 appropriate Groups of Experts or Working Parties of the Ph. Eur. 16 Review, where necessary, and maintenance of general chapter 5.15 FRCs of excipients to align 17 it with current regulatory guidance (e.g. ICH Q8 guideline) 18 Drafting and maintenance of the text on co-processed excipients 19 Review pharmacopoeial and other regulatory texts on general information on excipients with 20 a view to proposing necessary additions and updates, where relevant 21 Profile for experts 22 Current expertise in analytical procedures (especially those included in the Ph. Eur. section 2.9. 23 Pharmaceutical technical procedures), related to control of excipients and in development of 24 such analytical procedures 25 Several years of experience in one or more of the following fields: 26 Quality control of excipients in a bulk or pharmaceutical manufacturing setting 27 Pharmaceutical and excipient research and development 28 Assessment of the relevant parts of applications for marketing authorisation within a 29 medicines agency 30 Development of analytical procedures for control of excipients, comprising those to 31 determine excipient performance (FRCs) in a research and development environment 32 Pharmaceutical quality control in an independent testing laboratory 33 **EXS Working Party (Excipient Strategy)** 34 Terms of reference 35 Identify and discuss best possible approach(es) to address the quality and the standard setting process of excipients for pharmaceutical use in the Ph. Eur. in view of making concrete 36 recommendations to the Ph. Eur. Commission. 37 38 This would include, but is not limited to: 39 the typical structure and content of an individual monograph on such an excipient

the evaluation of the need for optional test(s) depending on the possible uses of the

the evaluation of the need for (a) specific technical guide(s)

excipients (e.g. FRC section)

1 o the review of terms of reference of groups of experts and working parties dealing with 2 such excipients (including repartition of tasks between groups and ways of working 3 between groups), 4 o The review of existing general monographs (such as Substances for pharmaceutical 5 use (2034)) to appropriately cover such excipients Considering the recent example of *nitrites in excipients*, the specific challenges related to 6 7 setting specifications for excipients in the Ph. Eur., the discussion around impurities (to cite 8 some examples), propose appropriate control strategies for excipients and consequently, 9 approaches for elaboration and revision of Ph. Eur. Monographs (general or individual ones)

## Profile for experts

10

11 12

13

1415

16

17

18

19

20

21

23

25

27

2829

30

3132

33

34

35

36

37

38

39

41

- Ideally a representative (e. g. Chairs) of each group dealing with excipients (esp. groups 9, 13H and CEL, CRB, EXP working party)
- Current expertise in pharmaceutical analytical procedures, related to quality control of excipients for pharmaceutical use and in development of such analytical procedures
- Several years of experience with excipients in one or more of the following fields:
  - Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  - Market surveillance testing
  - o Quality control or development of excipients for pharmaceutical use
  - o Development and verification of analytical procedures

and/or general chapters for excipients for pharmaceutical use

The EXS WP may preferably be chaired by a member of the Ph. Eur. Commission.

#### GLS Working Party (Glass Containers)

- 24 Terms of reference
  - Drafting and revision of texts in the field of glass containers
- 26 Profile for experts
  - Current expertise in the production of glass containers, analytical procedures, related to quality control of glass containers and in development of such analytical procedures
  - Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in general chapters
  - Several years of experience in one or more of the following fields:
    - Quality control in a pharmaceutical manufacturing setting for control of glass containers
      - Production and/or quality control of glass containers in an industrial setting
    - Market surveillance of quality in a regulatory authority
    - o Pharmaceutical quality control in an independent testing laboratory
  - Development of analytical procedures for control of glass containers in a research and development environment

# **GTP Working Party (Gene Therapy Products)**

- 40 Terms of reference
  - Drafting and revision of texts in the field of gene therapy medicinal products

39

40

41

42

within an agency

laboratory

1 Maintaining regular exchanges to ensure coordination of approaches with the CTP Working 2 Party in relevant areas 3 Profile for experts 4 Current expertise in analytical procedures related to development and quality control of gene 5 therapy products and in development of such analytical procedures Several years of experience in one or more of the following fields: 6 7 Development of gene therapy products 8 Quality control of gene therapy products in a pharmaceutical manufacturing setting 9 or in a hospital environment Assessment of applications for marketing authorisation of gene therapy products 10 Marketing surveillance of quality in a regulatory authority 11 12 Pharmaceutical quality control in an independent testing laboratory 13 Development of analytical procedures for control of gene therapy products in a 14 research and development environment 15 0 16 **HMM Working Party (Homoeopathic Manufacturing Methods)** 17 Terms of reference Drafting and revision of monographs in the field of homoeopathic manufacturing methods 18 19 Profile for experts 20 Knowledge of currently used homoeopathic manufacturing methods 21 Several years of experience in one or more of the following fields: 22 Assessment of application for marketing authorisation of homoeopathic products 23 within a medicines agency or equivalent 24 Industry representatives are normally not appointed to the HMM Working Party. They may be 25 invited to contribute to elaboration of monographs during hearings organised on a case-bycase basis by the Secretariat 26 27 **HOM Working Party (Homoeopathic Raw Materials and Stocks)** Terms of reference 28 29 • Drafting and revision of texts in the field of homoeopathic raw materials and stocks Profile for experts 30 31 Current expertise in pharmaceutical analytical procedures, related to quality control of 32 homoeopathic raw materials and stocks and in development of such analytical procedures 33 Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of 34 35 analytical procedures and drafting of texts 36 Several years of experience in one or more of the following fields: 37 Quality control of homoeopathic raw materials and stocks in a pharmaceutical 38 manufacturing setting

Assessment of applications for marketing authorisation of homoeopathic products

Quality control of homoeopathic raw materials and stocks in an independent testing

1 Development of analytical procedures for control of homoeopathic raw materials and 2 stocks in a research and development environment 3 Analytical procedure development, and verification in a regulatory authority 4 HTS Working Party (High Throughput Sequencing for the detection of extraneous agents) 5 Terms of reference Elaboration of general chapter 2.6.41 to describe High Throughput Sequencing (HTS) methods 6 7 for the detection of extraneous agents and provide guidelines for their validation 8 To advise the Commission and Groups of Experts on the need to revise other Ph. Eur. texts, 9 further to the elaboration of general chapter 2.6.41 and provide support to Group of Experts 10 requiring the inclusion of HTS methods for extraneous agent detection in their texts 11 Profile for experts 12 Current expertise in HTS for the detection of extraneous agents in biologicals, and in the 13 development and validation of analytical procedures based on HTS 14 Several years of experience in one or more of the following fields: 15 Use of HTS techniques for quality control of biological products in a pharmaceutical manufacturing setting, a regulatory authority or an independent testing laboratory 16 17 Development and validation of analytical procedures based on HTS for the detection 18 of extraneous agents, in a research and development environment 19 Assessment of the relevant parts of applications for marketing authorisation within a 20 medicines agency 21 **INH Working Party (Inhalations)** 22 Terms of reference 23 Drafting and revision of monographs and general chapters in the field of preparations for 24 inhalation and nasal sprays or powders. 25 International harmonisation of related general chapters 26 Profile for experts 27 Current expertise in pharmaceutical analytical procedures, related to quality control of 28 preparations for inhalation and nasal sprays or powders and in development of such analytical 29 procedures 30 Several years of experience in one or more of the following fields related to preparations for 31 inhalation and nasal sprays or powders: 32 Quality control in a pharmaceutical manufacturing setting 33 Market surveillance of quality in a regulatory authority

Assessment of applications for marketing authorisation within a medicines agency

Pharmaceutical quality control in an independent testing laboratory

Analytical procedure development and verification in a regulatory authority

and development environment

Development of analytical procedures for control of such preparations in a research

34

35

3637

#### MAB Working Party (Monoclonal Antibodies)

2 Terms of reference:

1

3

4

5

6

8

9

10

11

12

13 14

15

16

17

18

1920

21

23

2425

26

27

28 29

30

31

32

33

34

3536

37

38

39

40

- To undertake a pilot phase to elaborate general methods for analysis of monoclonal antibodies and individual monographs using the multisource approach (according to document PA/PH/Exp. MAB/T (14) 1)
- Drafting and revision of texts in the field of monoclonal antibodies

## 7 Profile for experts

- Current expertise in pharmaceutical analytical procedures, related to quality control of monoclonal antibodies and in development of such analytical procedures
- Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs or access to licensing files. Essential: Active involvement in laboratory verification of analytical procedures and drafting of texts
- Several years of experience in one or more of the following fields:
  - Quality control of monoclonal antibodies in a pharmaceutical manufacturing setting
  - Market surveillance of quality in a regulatory authority
  - Assessment of applications for marketing authorisation of monoclonal antibodies within an agency
  - Development of analytical procedures for control of monoclonal antibodies in a research and development environment
  - Pharmaceutical quality control in an independent testing laboratory

#### MG Working Party (General methods)

# 22 Terms of reference

- Drafting and revision of general chapters, particularly in the field of chemical and physicochemical analysis.
- If needed, requests the nomination of ad hoc specialists to create sub-groups for specific general chapters on the work programme, and management of the activities for the elaboration or revision of these general chapters within the sub-groups.
- Co-operation with other groups of experts and working parties which are in charge of elaboration and revision of general chapters where relevant.
- Maintenance of template for general methods

# Profile for experts

- Members of a regulatory authority, universities or the pharmaceutical/chemical industries
- Current expertise and extensive knowledge in pharmacopoeial procedures and/or instruments used in the quality control of active substances, excipients and/or medicinal products and in development of analytical procedures
- Several years of experience in one or more of the following fields:
  - Analytical procedure development and verification in e.g. analytical or pharmaceutical development, a regulatory authority, or testing laboratory
  - o Quality control of active substances, excipients and/or medicinal products
  - Market surveillance of quality of medicinal products in a regulatory authority

#### mRNAVAC Working Party (mRNA Vaccines for human use)

2 Terms of reference

1

3

5

6

7

8 9

10

11

12

13

14

1516

17

18

20

21

23

24

25

2627

28 29

3031

32

33

3536

37

38

- Drafting and revision of texts in the field of mRNA vaccines for human use
- 4 Profile for experts
  - Current expertise in analytical procedures related to the quality control of mRNA vaccines for human use, their components and their formulation
  - Significant experience in one or more of the following fields:
    - Quality control of mRNA vaccines for human use and their components in a pharmaceutical manufacturing setting
    - Quality control/batch release/market surveillance of mRNA vaccines for human use and their components in an independent testing laboratory (e.g. OMCL)
    - Pharmaceutical development related to the formulation of mRNA vaccines for human use
    - Analytical development related to mRNA vaccines for human use and their components
    - Assessment of the relevant parts of applications for marketing authorisation within a medicines agency

#### MYC Working Party (Mycoplasma)

- 19 Terms of reference
  - Revision of general chapter 2.6.7 Mycoplasmas in order to update it with the current practices in the field of mycoplasma testing
- 22 Profile for experts
  - Current expertise in mycoplasma testing of medicinal products and in development of analytical procedures
  - Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs,
  - Several years of experience in one or more of the following fields:
    - Mycoplasma testing in a pharmaceutical manufacturing setting
    - Mycoplasma testing in an official control laboratory for medicines
    - Mycoplasma testing in an independent testing laboratory
  - Development of analytical procedures for mycoplasmas in a research and development environment

## NANO Working Party (Nanomedicines)

- 34 Terms of reference
  - Drafting and revision of texts in the field of nanomedicines (e.g. nanoparticle dispersions, like for example iron sucrose concentrated solution, liposomal formulations, and related analytical procedures)
  - Provision of expertise in the field of nanomedicines to other groups where relevant
- 39 Profile for experts
- Current expertise in the development and/or quality control of nanomedicines and in development of relevant analytical procedures

1

2

3

4

5

6

7

8

9

10 11

12

14

16 17

18

19

20

21

22

23

24

25

2627

28

29

32

3334

35

37

38

39

40 41

42

43

- Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of analytical procedures and drafting of texts
- Several years of relevant experience in one or more of the following fields:
  - Quality control in a pharmaceutical manufacturing setting or in an independent testing laboratory (e.g. Market surveillance of quality in a regulatory authority) related to respective formulations
  - Pharmaceutical development related to respective formulations
  - Development of analytical procedures related to respective formulations
  - Assessment of the relevant parts of applications for marketing authorisation within a medicines agency

#### P4BIO Working Party (P4 Bio)

- 13 Terms of reference
  - Drafting and revision of monographs in the field of single-source biologicals
- 15 Profile for experts
  - Group P4Bio is restricted to regulators from Ph. Eur. Member states however industry representatives may be invited to contribute by submission of data and interaction with the group via the Secretariat
  - Current expertise in pharmaceutical analytical procedures, related to quality control of biologicals and in development of such analytical procedures
    - Access to laboratory facilities for verification and validation of analytical procedures proposed
      for inclusion in monographs or access to licensing files (essentially originating from CAP),
       Essential: Active involvement in laboratory verification of analytical procedures and drafting
      of texts and
    - Several years of experience in one or more of the following fields:
      - Quality control in a regulatory authority
      - Assessment of the relevant parts (biologicals) of applications for marketing authorisation
      - o Market surveillance of quality in a regulatory authority

## 30 PaedF Working Party (European Paediatric Formulary)

- 31 Terms of reference
  - Elaboration, and revision of monographs on paediatric preparations according to criteria and guidelines approved by the CD-P-PH
  - Establishment and maintenance of a Technical Guide for the elaboration and maintenance of monographs on paediatric preparations
- 36 Profile for experts
  - Current expertise in development and production of paediatric preparations (including toxicologists)
  - Current expertise in analytical procedures related to quality control of ingredients (APIs and excipients) and preparations and in the development of such preparations and analytical procedures; Access to laboratory facilities for verification of production methods and analytical procedures proposed for inclusion in monographs
  - Current expertise in clinical/pharmacological treatment of several paediatric age groups

- Several years of experience in one or more of the following fields:
  - Pharmaceutical development and/or manufacturing of paediatric preparations (in a community or hospital pharmacy, research unit, or in pharmaceutical industry)
  - Analytical procedure development and verification of medicinal preparations in a pharmaceutical manufacturing setting (including research and development), in a regulatory authority, in a community or hospital pharmacy or in an independent testing laboratory
  - Market surveillance of quality in a regulatory authority
  - Assessment of the relevant parts of applications for marketing authorisation of paediatric medicinal products (including safety assessment)
  - o Elaboration/assessment of monographs for national (paediatric) formularies
  - o Clinical/pharmacological treatment of children belonging to several age groups

## PAT Working Party (Process Analytical Technology)

## Terms of reference

1

2

3

4

5

6 7

8

9

10

11

12

13

14

15

16

1718

19

20

21

2223

2425

26

27

28

29

30

3132

33

3637

38

39

40 41

42

43

44

- Review and revision of existing general monographs and chapters in view of needs arising from Process Analytical Technology (PAT), Continuous Manufacturing (CM), Real Time release testing (RTRT) or Quality by Design (QbD) concepts
- Identify and discuss the implication of the above mentioned concepts on the texts of European Pharmacopoeia and make proposals to the Commission where needed
- Support and advise other group of experts and working parties where elements of the above mentioned concepts are concerned.

#### Profile for experts

- Expertise in chemical or pharmaceutical development and analytical procedures applied during manufacture and to active substances or finished pharmaceutical preparations
- Several years of experience in one or more of the following fields
  - Development of pharmaceutical preparations using PAT, CM, RTRT or QbD concepts in an industrial setting
  - Assessment of the relevant parts of applications for marketing authorisation containing PAT, CM, RTRT or QbD concepts within a medicines agency
  - o Development of control strategies including PAT, CM, RTRT or QbD concepts approaches for testing of active substances or pharmaceutical preparations
  - Development of pharmaceutical preparations using modelling and chemometrics associated with the analytical aspects for PAT

# 34 POW Working Party (Powder Characterisation)

- 35 Terms of reference
  - Drafting and revision of general chapters in the field of powder characterisation techniques
  - International harmonisation of general chapters

#### Profile for experts

- Current expertise in analytical procedures for powder characterisation, related to quality control of active substances and excipients and in development of such analytical procedures
- Several years of experience in one or more of the following fields:
  - Quality control of active substances and excipients in a pharmaceutical manufacturing setting
  - Assessment of the relevant parts of applications for marketing authorisation

1 Market surveillance of quality in a regulatory authority 2 o Development of analytical procedures for characterisation of powders in a research and development environment 3 4 Pharmaceutical quality control in an independent testing laboratory 5 PRP Working Party (Precursors for Radiopharmaceutical Preparations) 6 Terms of reference 7 Drafting and revision of texts in the field of non-radioactive precursors for 8 radiopharmaceutical preparations 9 Profile for experts 10 Expertise in chemical, pharmaceutical and radiopharmaceutical analytical procedures, related to quality control of radiopharmaceutical preparations and their precursors 11 Access to laboratory facilities for verification and validation of analytical procedures proposed 12 for inclusion in monographs. Essential: Active involvement in laboratory verification of 13 14 analytical procedures and drafting of texts 15 Several years of experience in one or more of the following fields: Quality control of radiopharmaceutical preparations and their precursors 16 17 Quality control of synthetic organic and/or inorganic products in a chemical or 18 pharmaceutical setting 19 Quality control in an independent testing laboratory 20 Development of analytical procedures for the control of radiopharmaceutical 21 preparations and their precursors **PST Working Party (Pesticide Residues)** 22 23 Terms of reference 24 • Drafting and revision of texts in the field of pesticide residues 25 *Profile for experts* 26 Current expertise in pesticide analysis, related to quality control of active substances and 27 excipients and in development of such analytical procedures 28 Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs 29 30 Several years of experience in one or more of the following fields: 31 Quality control for pesticide residues in herbals in a pharmaceutical or bulk 32 manufacturing setting 33 Market surveillance of quality in a regulatory authority Pharmaceutical quality control in an independent testing laboratory 34 35 Development of analytical procedures for pesticide residues in a research and

# **ROP Working Party (Rules of Procedure)**

development environment

# 38 Terms of reference

36

37

39

40

41

• Elaborating any document or updating existing ones (Rules of Procedure, Guide for work of the European Pharmacopoeia, Code of Practice) in line with the decisions taken by the Commission.

 Supporting the implementation of the revised documents (e.g. in form of powerpoint presentations, webinars or any other mean deemed appropriate by the ROP WP members to ensure consistent and appropriate dissemination of the information provided and changes made as well as their application)

# Profile for experts

1

2

3

4

5

6

7

9

1011

12

13 14

15

16

1718

19

20

21

22

23

24

25

26

27

28

29

30

31

32 33

34

35

36

37

38 39

40

41

- Members of national pharmacopoeia authorities of a Ph. Eur. Member state or delegations to the Commission.
- 8 The ROP WP is chaired by the Chair of the Ph. Eur. Commission.

## SDA Working Party (Spectroscopy and Data Analysis)

#### Terms of reference

- Drafting and revision of general chapters in the fields of:
  - Measurement techniques relying on spectroscopy, with the exception of specific spectroscopic techniques where the drafting and revision of general chapters is allocated to other, more specialised groups of experts and working parties.
  - Chemical imaging techniques, e.g. spectral and multispectral imaging, electron microscopy, field effect and atomic force microscopies, optical and X-ray tomography, etc.
  - Chemometrics and data sciences techniques relying on multivariate data analysis, numerical methods, algorithmics, data modelling, data mining, artificial intelligence, etc., and image analysis techniques.
- to support and advise other group of experts and working parties where elements of the above mentioned measurement and data analysis techniques are concerned and where relevant.

## Profile for experts

- Current expertise in spectroscopy related to quality control of active substances, excipients or medicinal products, in development of analytical procedures.
- Ideally, access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in general chapters and monographs
- Several years of experience in one or more of the following fields:
  - Use of spectroscopic techniques for pharmaceutical quality control in a pharmaceutical manufacturing setting, a regulatory authority or an independent testing laboratory.
  - Development of pharmaceutical in-, on-, or at-line analytical procedures using spectroscopic or imaging techniques or chemometrics and data analysis, in a research and development environment.
  - o Assessment of applications for marketing authorisation.
  - Use of spectroscopic techniques for the market surveillance of the quality of pharmaceutical substances or medicinal products.

# SIT Working Party (Second identification test)

## Terms of reference

- To support and advise the Commission, Groups of Experts or Working Parties on revision/suppression of existing identification series, notably arising from the REACH regulation, where relevant.
- 42 Propose to the Commission further items for the work programme (such as monographs with 43 missing second identification or the replacement of identification tests not in line with the 44 instrumentation available in pharmacies)

2

3

4

5

6

7

8

9

12

13

14

15

17

18 19

20

21

22

23

24

27

29

30

31

32

33

36

37

38

- Pharmacists regularly involved in preparation of extemporaneous or stock preparation of medicinal products in community pharmacies or hospitals as well as in the analysis of the pharmaceutical substances used
- Pharmacists or chemists with special interest/expertise in analytical techniques commonly available in pharmacies
  - Members of a regulatory authority
  - Access to laboratory facilities for verification of analytical procedures proposed for inclusion in monographs

## 10 ST Working Party (Standard Terms)

- 11 Terms of reference
  - Development of standard terms and definitions for the Standard Terms database for dosage forms, units of presentation, routes of administration, packaging and related terms at the request of Competent authorities of Member States and certain non-member states (e.g. competent authority members of ICH), the European Commission or the EMA.
- 16 Profile for experts
  - Current expertise in pharmaceutical dosage forms
  - Several years of experience in one or more of the following fields:
    - Assessment of the pharmaceutical development part of applications for authorisation of medicinal products
      - Development of general monographs for dosage forms (group of experts or national pharmacopoeia secretariat)
      - Experience in formulation of medicinal products
  - Members of the working party may be from a regulatory authority or universities

#### 25 **SUT Working Party (Sutures)**

- 26 Terms of reference
  - Drafting and revision of texts in the field of sutures
- 28 Profile for experts
  - Expertise in pharmaceutical analytical procedures, related to quality control of sutures and in development of such analytical procedures
    - Several years of experience in one or more of the following fields:
      - Quality control of sutures
      - Development of analytical procedures for control of sutures

#### **TCM Working Party (Traditional Chinese Medicines)**

- 35 Terms of reference
  - Drafting and revision of texts in the field of herbal drugs and herbal drug preparations
    preferably based on the principle of adapting/improving existing monographs or analytical
    procedures to control herbal drugs used in Traditional Chinese Medicines (TCM)
- Drafting general chapters related to the specific needs of TCM herbal drugs

1

2

3

4

5

6

7

8 9

1011

12

13

14

15

16 17

18

19

21

23

24

25

26

27

2829

30

31

3233

3435

36

37

39

- Current expertise in pharmaceutical analytical procedures, related to quality control of herbal drugs and herbal drug preparations and in development of such analytical procedures
- Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs
- Several years of experience in one or more of the following fields:
  - Quality control of herbal drugs/herbal drug preparations in a manufacturing setting
  - Pharmaceutical quality control of herbal drugs and herbal drug preparations in an independent testing laboratory
  - o Development and validation of analytical procedures for control of herbal drugs
  - Involvement in market surveillance or regulatory oversight of imported TCM herbal drugs
- **Essential**: Active involvement in laboratory verification of analytical procedures for TCM herbal drugs and in drafting of texts.
- Development and validation of analytical procedures for identification and/or quantification of herbal drug constituents based on chromatographic separation techniques (HPLC, GC, HPTLC)
- Knowledge in cultivation, harvesting, processing and use of TCM herbal drugs

#### VIT Working Party (Vitamins)

- 20 Terms of reference
  - Drafting and revision of monographs in the field of vitamins and vitamin derivatives
- 22 Profile for experts
  - Current expertise in pharmaceutical analytical procedures, related to quality control of vitamins and excipients and in development of such analytical procedures. The need of a specialist for vitamin D type substances is highlighted
  - Access to laboratory facilities for verification and validation of analytical procedures proposed for inclusion in monographs, Essential: Active involvement in laboratory verification of analytical procedures and drafting of texts.
  - Several years of experience in one or more of the following fields:
    - Quality control of vitamins in a pharmaceutical or bulk manufacturing setting
    - Market surveillance of quality in an official control laboratory for medicines
    - o Pharmaceutical quality control in an independent testing laboratory
    - Development of analytical procedures for control of vitamins in a research and development environment
    - Analytical procedure development and verification in a national pharmacopoeia laboratory

## WAT Working Party (Water)

- 38 Terms of reference
  - Drafting and revision of texts in the field of water
- International harmonisation of relevant texts

2

3

4

5 6

7

8

- Current expertise in analytical procedures applicable to water analysis and in development of such analytical procedures
- Several years of experience in one or more of the following fields:
  - o Quality control of water in a pharmaceutical manufacturing setting
  - Inspection of manufacturing sites
  - o Pharmaceutical quality control in an independent testing laboratory
  - Development of analytical procedures for control of pharmaceutical waters in a research and development environment